Thyroid hormone (TH) is critical for the maintenance of cellular homeostasis during stress responses, but its role in lung fibrosis is unknown. Here we found that the activity and expression of iodothyronine deiodinase 2 (DIO2), an enzyme that activates TH, were higher in lungs from patients with idiopathic pulmonary fibrosis than in control individuals and were correlated with disease severity. We also found that Dio2-knockout mice exhibited enhanced bleomycin-induced lung fibrosis. Aerosolized TH delivery increased survival and resolved fibrosis in two models of pulmonary fibrosis in mice (intratracheal bleomycin and inducible TGF-b1). Sobetirome, a TH mimetic, also blunted bleomycin-induced lung fibrosis. After bleomycin-induced injury, TH promoted mitochondrial biogenesis, improved mitochondrial bioenergetics and attenuated mitochondria-regulated apoptosis in alveolar epithelial cells both in vivo and in vitro. TH did not blunt fibrosis in Ppargc1a-or Pink1-knockout mice, suggesting dependence on these pathways. We conclude that the antifibrotic properties of TH are associated with protection of alveolar epithelial cells and restoration of mitochondrial function and that TH may thus represent a potential therapy for pulmonary fibrosis.
Pulmonary fibrosis describes a condition in which the normal lung anatomy is replaced by a process of active remodeling, deposition of extracellular matrix and dramatic changes in the phenotype of both fibroblasts and alveolar epithelial cells. This condition can be idiopathic, as in idiopathic pulmonary fibrosis (IPF), or secondary to genetic disorders, autoimmune disorders or exposure to environmental toxins, chemical warfare, drugs, foreign antigens or radiation 1 . IPF represents the most common, idiopathic form of pulmonary fibrosis and is frequently pathologically indistinguishable from the other forms, especially at later stages of disease. IPF affects approximately 120,000 people in the United States, with a steady increase in both incidence and mortality in recent years. The median survival time for IPF without transplant is approximately 3 years, making it the noncancer-related lung disease with the gravest prognosis 2 .
IPF is the result of multiple cycles of epithelial cell injury and activation that provoke the formation of myofibroblastic foci, accumulation of extracellular matrix and abnormal wound repair 3 . Multiple pathways, including sustained transforming growth factor (TGF)-β1 activation, abnormal matrix deposition, epithelial injury and apoptosis, fibroblast activation and myofibroblast transdifferentiation, aberrant recapitulation of developmental pathways, endoplasmic reticulum stress, telomerase mutations, oxidative injury, and metalloprotease activation and signaling 4 , as well as extensive changes in mRNA 5 and microRNA 6 expression, have been implicated in IPF. More recently, it has been proposed that many of these features could be explained by aging and, indeed, many of the hallmarks of aging, including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion and altered intercellular communication, can be considered characteristics of the fibrotic lung 7, 8 .
In the context of this study, the emerging evidence for mitochondrial dysfunction and metabolic aberrations in pulmonary fibrosis were very compelling 8 . Metabolic reprogramming is a characteristic of myofibroblast differentiation 9,10 , alveolar epithelial cells in IPF lungs exhibit large numbers of damaged mitochondria 11 , and increased levels of free mitochondrial DNA are found in the plasma and bronchoalveolar lavage of subjects with IPF 9 . Levels of PTENinduced putative kinase 1 (PINK1), a regulator of mitophagy, are lower in the lungs of subjects with IPF than in healthy controls, and Pink1-knockout mice exhibit deformed mitochondria and are more susceptible to pulmonary fibrosis than wild-type mice 11 . Considering that the original observation of PINK1 downregulation in IPF was derived from a public data set generated by us (http://www.lung-genomics.org/; GEO accession GSE47460) 12 , we looked for other changes in gene expression indicative of abnormalities in lung bioenergetics or metabolism. We discovered that DIO2, encoding the iodothyronine deiodinase that converts the prohormone thyroxine (T 4 ) to the active molecule 3,5,3′-triiodothyronine (T 3 ), was among the genes with the most significantly increased expression in the lungs of individuals with IPF.
The purpose of the current study was to follow up on this finding and investigate the role of TH signaling in the pathogenesis of experimental and human pulmonary fibrosis and its potential effects on mitochondrial function in IPF. In brief, we discovered that upregulation of DIO2 in the lungs of patients with IPF most likely represents an effort to boost local conversion of T 4 to T 3 as a means to improve the metabolic state of alveolar epithelial cells in the stressed environment of the fibrotic lung. Dio2-knockout mice exhibited enhanced bleomycin-induced pulmonary fibrosis, whereas aerosolized delivery of TH blunted fibrosis in two experimental mouse models. The beneficial effects of TH in mouse pulmonary fibrosis were associated with normalization of mitochondrial function and morphology in alveolar type II epithelial cells (AECIIs). T 3 -mediated reversal of bleomycininduced mitochondrial abnormalities was associated with inhibition of mitochondria-regulated apoptosis in lung epithelial cells in vivo and in vitro and was dependent on intact expression of regulators of mitochondrial biogenesis and mitophagy, including peroxisome proliferator-activated receptor γ co-activator α (PGC-1α) and PINK1. These effects may potentially be mediated through interaction of T 3 with thyroid hormone receptors (TRs), given that we found that a TR-selective thyromimetic compound had antifibrotic properties in the bleomycin model of lung fibrosis.
RESULTS
DIO2 expression and activity are higher in IPF and absence in mice augments pulmonary fibrosis Reanalysis of the Lung Genomic Research Consortium (LGRC) data set identified DIO2 as being among the genes with the most significantly increased expression in lungs from patients with IPF as compared to controls ( Fig. 1a and Supplementary Table 1 ).DIO2 gene expression was negatively correlated with disease severity, as reflected by diffusion capacity for carbon monoxide (DLCO % predicted) ( Fig. 1b) . DIO2 mRNA ( Fig. 1c ) and protein ( Fig. 1d ) levels were significantly higher (eight-and threefold, respectively) in the lungs of patients with IPF than in normal-histology controls (P < 0.001). DIO2 enzymatic activity, assessed by in vitro T 4 to T 3 conversion, was also higher (threefold, P < 0.05) in lung extracts from patients with IPF than in controls ( Fig. 1e) . DIO2 was mainly expressed in the alveolar epithelium surrounding the fibrotic interstitium in lungs from patients with IPF and was weakly expressed in normal alveolar epithelium ( Fig. 1f) . In line with the human data, DIO2 expression ( Fig. 1g ) and activity ( Fig. 1h) were also significantly induced in the bleomycin model of lung fibrosis in mice.
To determine the role of increased DIO2 levels in human lung fibrosis, we administered bleomycin to Dio2-knockout (Dio2 −/− ) mice, which are systemically euthyroid but exhibit localized hypothyroidism in tissues that normally express DIO2 (refs. 13,14) . Both Dio2 −/− mice and wild-type littermates developed pulmonary fibrosis by 14 d after intratracheal bleomycin administration, with significant increases in hydroxyproline levels (1.7-and 1.6-fold, respectively) ( Fig. 1i ) as compared to saline-treated animals. However, after bleomycin administration, Dio2 −/− mice exhibited significantly higher hydroxyproline levels (1.3-fold) indicative of increased deposition of collagen in the lung ( Fig. 1i ) and showed increased histological evidence of fibrosis in the lung (Fig. 1j ) as compared to wild-type littermates, but no increases in collagen mRNA levels (data not shown).
Thyroid hormone blunts lung fibrosis in two mouse models
Systemic administration of T 4 (100 µg per kg body weight, µg/kg) at days 10, 12, 14 and 16 after bleomycin administration significantly blunted fibrosis but caused a significant increase in serum T 3 levels ( Supplementary Fig. 1) . To avoid the side effects of systemic administration of T 4 and maximize therapeutic efficacy, we focused on pulmonary delivery by aerosol of the physiologically active T 3 hormone. Therapy with aerosolized T 3 (40 µg/kg), given every other day starting at the stage of established fibrosis (days 10-20 after bleomycin administration), caused a significant decrease in hydroxyproline levels (2.25-fold, P < 0.05) ( Fig. 2a ) and reduction of histological evidence of fibrosis ( Fig. 2b) , without affecting serum T 3 levels (Fig. 2c) . The effects were comparable to those observed with oral administration of pirfenidone (100 mg per kg body weight, mg/kg) or nintedanib (60 mg/kg), the two drugs currently approved by the US Food and Drug Administration (FDA) for treatment of human IPF 15 ( Fig. 2a,b) .
Aerosolized T 3 therapy reversed the significant reduction in static lung compliance induced by bleomycin, reflecting a functional improvement in respiratory mechanics and reduction in fibrosis ( Fig. 2d ). Similar functional benefits were observed with pirfenidone and nintedanib treatment (data not shown). To observe the effects of aerosolized T 3 on survival, we used a higher dose of bleomycin (3.0 U per kg body weight, U/kg). In contrast to pirfenidone and nintedanib, aerosolized T 3 resulted in a substantial survival benefit, with a significant reduction in mortality from 90% in the untreated group to 20% in the T 3treated arm ( Fig. 2e) . This survival benefit suggests that T 3 potentially limits the extent of acute lung injury caused by high-dose bleomycin in addition to having antifibrotic effects. To assess the effects of aerosolized T 3 in another experimental animal model of lung fibrosis, we used triple-transgenic mice in which the Scgb1a1 (CC10) promoter drives the expression of active TGF-β1 in response to doxycycline treatment 16 . Aerosolized T 3 therapy, given every other day at days 10-20 after the start of doxycycline treatment, resulted in significantly lower pulmonary fibrosis as demonstrated by lower hydroxyproline levels (1.15-fold, P < 0.05) and weaker Masson's trichrome staining in comparison to mice treated with doxycycline and vehicle ( Fig. 2f,g) .
Thyroid hormone reverses bleomycin-induced mitochondrial abnormalities
As previously observed 11 , AECIIs in bleomycin-treated mice exhibited swollen mitochondria with severely damaged electron-lucent cristae and disrupted membranes and significantly reduced numbers of normal-looking mitochondria, and aerosolized T 3 reversed these changes ( Fig. 3a,b) . Aerosolized T 3 also reversed many of the functional abnormalities induced by bleomycin in AECIIs. Specifically, primary AECIIs isolated on day 21 from the lungs of bleomycintreated mice (AECBs) exhibited significantly lower mitochondrial membrane potential (MMP) than AECIIs from mice treated with aerosolized T 3 after bleomycin (AECBT3s) or AECIIs isolated from uninjured lungs (AECTRLs) (1.4-and 1.5-fold, respectively) ( Fig. 3c) . AECBs exhibited a significantly decreased oxygen consumption rate (OCR) as compared to AECTRLs (threefold) that was restored to baseline levels in AECBT3s (Fig. 3d) . In vitro, bleomycin treatment caused significant declines in the mitochondrial bioenergetic profile of primary human small airway epithelial cells (SAECs), primary mouse lung AECIIs and mouse lung epithelial cells (MLE-12), but T 3 , added 4 h after bleomycin, reversed this decline. SAECs, AECIIs and MLE-12 cells that were treated with T 3 after bleomycin exhibited significantly higher MMP (1.2-, 1.3-and 1.3fold, respectively) ( Fig. 3e-g) and OCR (2.1-, 1.5-and 6.9-fold, respectively) ( Fig. 3h-j ) as compared to cells treated with vehicle after bleomycin. A detailed analysis of mitochondrial bioenergetic profiles in lung epithelial cells, both in vivo (isolated AECIIs) and in vitro (SAECs, AECIIs and MLE-12 cells), showed similar differences between T 3 -treated groups and controls ( Supplementary Fig. 2) .
To assess the effects of T 3 treatment on mitogenesis, we measured the ratio of cytochrome c oxidase, subunit IV (COX-IV) to succinate dehydrogenase complex flavoprotein, subunit A (SDHA), as previously described 17 . Epithelial cells treated with bleomycin exhibited a significantly lower COX-IV/SDHA ratio than cells treated with vehicle. Bleomycin-treated cells that were also treated with T 3 exhibited ratios similar to controls. This effect was observed in the SAEC, AECII and MLE-12 cell types (1.4-, 1.2-and 1.4-fold, respectively) ( Fig. 3k-m) . Epithelial cells treated with bleomycin exhibited significantly lower protein expression of PGC-1α, a transcriptional co-activator of mitochondrial metabolism and biogenesis, than vehicle-treated controls, but in cells treated with T 3 following bleomycin PGC-1α expression was similar to that in controls ( Fig. 3n) . T 3 treatment after bleomycin was associated with significantly higher levels of PINK1. Changes in autophagic flux, as indicated by altered autophagy protein light chain 3B (LC3B) and p62 protein levels, were consistently seen in SAECs but not in AECIIs or MLE-12 cells ( Fig. 3n) .
Thyroid hormone suppresses mitochondria-regulated apoptosis in AECIIs
After showing that TH opposes bleomycin-induced mitochondrial functional abnormalities in primary mouse epithelial cells in vivo and in both human and mouse epithelial cells in vitro, we aimed to determine the effects of TH treatment on mitochondria-regulated apoptotic pathways. Immunoblot analyses showed that exposure of AECIIs to bleomycin led to higher protein expression of the proapoptotic mediator BCL-2-associated X protein (BAX) and lower expression of the antiapoptotic mediator BCL-xL ( Fig. 4a) . Notably, bleomycin promoted the intracellular movement of BAX from the cytosol to mitochondria in SAECs, as indicated by colocalization of BAX with Mito-Tracker in immunofluorescence analysis ( Fig. 4b) . BAX upregulation and mitochondrial translocation were associated with enhanced apoptotic activity, as demonstrated by increased numbers of TUNEL-positive cells ( Fig. 4c,d) . This observation was verified in vivo by immunohistochemistry analysis showing increased TUNEL staining in the alveolar epithelium in mouse lungs challenged with bleomycin ( Fig. 4e,f) . T 3 treatment reversed the BAX/BCL-xL ratio (Fig. 4a) , attenuated BAX translocation to mitochondria ( Fig. 4b) and consequently diminished bleomycin-induced apoptotic injury in AECs, both in vitro and in vivo, as indicated by significant reductions in TUNEL-positive cells ( Fig. 4c-e ). 
Antifibrotic effects of thyroid hormone are dependent on PGC-1a and PINK1
Expression of PGC-1α mRNA was lower following bleomycin administration in wild-type and Dio2 −/− mice as well as in human IPF lungs in comparison to controls (Supplementary Fig. 3 ). Mice treated with aerosolized T 3 after bleomycin exhibited significantly higher (1.5-fold) expression of Ppargc1a mRNA in their lungs than mice treated with vehicle after bleomycin ( Fig. 5a) . To determine whether the antifibrotic effects of T 3 were mediated through PGC-1α, we used Ppargc1a-knockout (Ppargc1a −/− ) mice. After bleomycin treatment, Ppargc1a −/− mice demonstrated significantly higher hydroxyproline levels (1.35-fold) than wild-type littermates, but similar changes in Col1a1 and Col3a1 mRNA levels ( Fig. 5b-d) . Unlike in wild-type littermates, aerosolized T 3 did not blunt fibrosis in Ppargc1a −/− mice, and hydroxyproline content, Col1a1 and Col3a1 mRNA levels, and Masson's trichrome staining were unchanged in comparison to vehicle-treated mice ( Fig. 5a-e ). Consistent with previous reports 18 , in vitro treatment with T 3 of A549 human alveolar epithelial cells induced higher expression of PGC-1α and a shift in its cellular localization from nuclear to both nuclear and mitochondrial ( Fig. 5f,g) . Dronedarone, an inhibitor of TRs 19 , blocked the T 3 -mediated induction and cellular redistribution of PGC-1α ( Fig. 5f,g) . TR inhibition by dronedarone also prevented the antiapoptotic effects of T 3 , as indicated by lower protein levels of BCL-xL and increased numbers of TUNEL-positive cells in immunofluorescence analysis (Fig. 5g,h) . Gold immunostaining for TR-α1 (encoded by Thra) and TR-β (Thrb) in uninjured mouse lungs localized both receptors to the nuclei and mitochondria of AECIIs (Fig. 5i) . To further support our hypothesis that T 3 antifibrotic properties are mediated through TRs, we investigated the therapeutic effects of sobetirome, a well-characterized TR agonist 20, 21 . Oral administration of sobetirome started 10 d after bleomycin treatment was associated with enhanced resolution of pulmonary fibrosis, as demonstrated by significantly decreased hydroxyproline content (P < 0.05) and decreased Masson's trichrome staining (Fig. 5j,k) . PINK1 is a known positive regulator of PGC-1α-dependent mitochondrial metabolism 22 , and its absence renders mice susceptible to lung fibrosis owing to an inability to process dysfunctional mitochondria through mitophagy 11 . After demonstrating that the antifibrotic effects of TH were dependent on PGC-1α, we assessed the role of PINK1. In wild-type mice, aerosolized T 3 treatment partially reversed bleomycin-induced PINK1 downregulation (1.8-fold increase) ( Fig. 6a) . Pink1-knockout (Pink1 −/− ) mice exhibited higher collagen deposition as measured by hydroxyproline levels (1.28-fold) (Fig. 6b) , Col1a1 mRNA levels (1.5-fold) (Fig. 6c,d) and Masson's trichrome staining (Fig. 6e) as compared to wild-type mice, indicating augmented fibrosis, as previously reported 11 . Administration of aerosolized T 3 did not blunt bleomycin-induced lung fibrosis in Pink1 −/− mice ( Fig. 5b-e ).
DISCUSSION
Our results here suggest that mitochondrial dysfunction, increasingly recognized as a hallmark of epithelial cell injury in pulmonary fibrosis 11 , can be attenuated using localized TH delivery, leading to resolution of fibrosis in mouse models. Following the observation that both the expression and activity of DIO2 were substantially increased in lungs from patients with IPF and correlated with disease severity, we studied the role of DIO2 and TH signaling in experimental pulmonary fibrosis in mice. Genetic deletion of DIO2 enhanced bleomycin-induced lung fibrosis. TH delivery to the lung blunted established pulmonary fibrosis in two experimental models, as did oral therapy with sobiterome, a well-characterized thyromimetic drug. TH reversed bleomycin-induced mitochondrial derangements in epithelial cells in vivo and in vitro through improved mitochondrial function and homeostasis. These beneficial effects were associated with suppression of mitochondria-regulated death pathways and dependent on intact PGC-1α and PINK1 pathways.
TH regulates fundamental biological functions, including bioenergetics and post-stress-injury repair of every vertebrate tissue. Tissuespecific TH metabolism and availability are tightly regulated by DIO1, DIO2 and DIO3. Among these, DIO2 is mainly responsible for TH activation by converting T 4 to active T 3 (ref. 23 ). Increased DIO2 expression and activity may reflect either TH deficiency or increased metabolic requirements 23 , whereas decreases reflect excess of TH in the body 23 . These changes are required to protect vital tissues and organs from unexpected fluctuations in TH levels. In the context of lung disease, DIO2 immunoreactivity and enzymatic activity were rapidly increased by ventilation-induced lung injury and Dio2knockout mice exhibit increased susceptibility to acute lung injury 24 . TH therapy significantly attenuated experimental lung injury 24 and produced similar therapeutic results in animal models of cardiac 25 and renal 26 injury. Clinically, hypothyroidism has been associated with unfavorable prognosis in critically ill patients 27 , myocardial infarction 28 , diabetic nephropathy 29 and, most recently, IPF 30 . However, evidence for impaired TH signaling in the human IPF lung or experimental evidence in support of its therapeutic utility in IPF was not available. Our study provides new observations that together establish the case for aerosolized TH as an antifibrotic therapy. First, we provide evidence that DIO2 expression and activity are increased in the lungs of patients with IPF, correlate with disease severity and localize mainly to airway epithelial cells, the highly metabolically active cell type thought to be at the center of the vicious cycle of injury and repair characteristic of IPF. Second, we establish a role for TH in experimental lung fibrosis: TH therapy effectively blunts experimental lung fibrosis in two mouse models in a manner that is replicated by the TH mimetic sobiterome. Third, a beneficial effect is observed when TH therapy is initiated during the established fibrosis phase, suggesting enhanced resolution of fibrosis. Fourth, the antifibrotic effects of TH are obtained with aerosolized T 3 without an increase in serum T 3 levels, suggesting that aerosolized delivery may be effective without the toxicity observed previously with systemic delivery 31 . The possibility of some systemic deposition of TH following aerosolized delivery could not be entirely excluded, as mice may clean their fur following mist exposure; yet, such deposition appears to be nonsignificant, as demonstrated by minimal changes in serum T 3 levels.
Lastly, aerosolized T 3 shows comparable or superior effects in lung fibrosis or survival in comparison to the two FDA-approved therapeutic compounds for the treatment of IPF, pirfenidone and nintedanib. Taken together, these observations establish a new role for TH as a potential therapeutic agent in pulmonary fibrosis.
Mechanistically, we established that TH exerts its antifibrotic effects in bleomycin-induced pulmonary fibrosis by restoring mitochondrial function through induction of mitochondrial biogenesis and mitophagy. T 3 -mediated beneficial effects on mitochondrial homeostasis attenuated bleomycin-induced mitochondria-regulated cell death in alveolar epithelial cells. Recently, there has been substantial interest in mitochondrial function in chronic lung diseases 9, 11, 32 . Bueno et al. discovered that the levels of PINK1, a regulator of the clearance of dysfunctional mitochondria, were decreased in subjects with IPF 11 . They convincingly demonstrated abundant mitochondrial abnormalities in AECIIs derived from the lungs of patients with IPF, as well as in mice treated with bleomycin 11 . On the basis of their findings, we hypothesized that the effects of TH depletion or augmentation on the severity of bleomycin-induced pulmonary fibrosis were associated with changes in mitochondrial function. Indeed, when we isolated primary mouse AECIIs from lungs treated with bleomycin, we discovered that they exhibited derangements in mitochondrial function, including diminished ATP production, ineffective energy metabolism and mitochondrial membrane depolarization, an index of mitochondrial integrity and the proton gradient across the mitochondrial inner membrane, and increased proton leak. Aerosolized TH treatment significantly improved all of the parameters of mitochondrial function, as well as mitochondrial morphology, in AECIIs. TH therapy did result in increased proton leak, but this correlated with increased coupling efficiency and metabolic rates, as has previously been observed 33 . This phenomenon may represent restoration of the basal mitochondrial adaptive mechanism to link higher proton conductance to higher metabolic rates, resulting in protection against excessive reactive oxygen species (ROS) production 34 .
In the context of critical illness, TH exerts cytoprotective and regenerative properties through effects on target genes leading to maintenance of cellular homeostasis, energy expenditure and modulation of stress responses to injury 35 . We propose a similar but more detailed model in pulmonary fibrosis, specifically, that repeated epithelial injury and increased metabolic demand lead to mitochondrial damage, increased ROS generation and epithelial cell apoptosis, eventually leading to fibroblast activation and initiation of the vicious fibrotic cycle. TH opposes these processes by mediating mitochondrial biogenesis and effective mitophagy through induction of the major transcriptional co-activators PGC-1α and PINK1. The role of PGC-1α and PINK1 in the beneficial effects of TH is of particular interest. PGC-1α controls mitochondrial remodeling and mitochondrial biogenesis 36 . PINK1 is downstream of PGC-1α and is thought to have an important role in regulating PGC-1α-dependent mitochondrial biogenesis through selective degradation of damaged mitochondria by mitophagy 22 . Both PGC-1α and PINK1 levels were decreased in the lungs of animals treated with bleomycin, and TH treatment restored them. Aerosolized TH delivery failed to rescue the bleomycin-induced fibrotic phenotype in mice with either PGC-1α or PINK1 deficiency, suggesting that TH-mediated antifibrotic effects require intact PGC-1α and PINK1. The relevance of this finding to human disease is enhanced because the expression of both molecules is decreased in human IPF lungs; however, it is unclear whether directly overexpressing either of the molecules will have any antifibrotic effect. In addition to our in vivo observations, we demonstrated in vitro that T 3 causes TR-dependent induction and redistribution of PGC-1α in alveolar epithelial cells, consistent with previous reports in other cells 37 . TR inhibition with dronedarone resulted in enhanced apoptotic activity and diminished TH-mediated PGC-1α induction and translocation, whereas treatment with TH restored mitochondrial bioenergetics and reduced apoptotic activity in lung epithelial cells.
Epithelial cell apoptosis and impaired autophagy are increasingly considered hallmarks of pulmonary fibrosis 16, 38 , and they are believed to reciprocally regulate each other 39 . Caspase-mediated apoptosis has been proposed to inhibit autophagy through cleavage of several autophagy-related proteins, including LC3B 40 . On the other hand, mitophagy reduces the propensity of cells to undergo apoptosis and functions as an early cytoprotective response favoring adaptation to stress and injury by removing damaged mitochondria. PINK1 acts as a key cytoprotective kinase that activates antiapoptotic members of the BCL-2 family 41 , which are known to act as positive regulators of mitochondrial bioenergetics by enhancing coupling efficiency and ATP production 42 . In line with these studies, we have demonstrated that alveolar epithelial cells exposed to bleomycin exhibit enhanced BAX mitochondrial translocation and diminished BCL-xL expression, mitochondrial membrane depolarization, and downregulation of PINK1 and PGC-1α, leading to impairment of mitophagy and mitochondrial biogenesis, as assessed by changes in the COX-IV/SDHA ratio. These in vitro observations were also supported by in vivo findings showing impaired mitochondrial homeostasis and enhanced apoptosis in AECIIs derived from mice challenged with bleomycin. Impressively, we observed that T 3 mediated a sequence of cytoprotective antiapoptotic events including attenuation of mitochondrial membrane depolarization, enhancement of mitochondrial biogenesis, induction of effective mitophagy and, finally, suppression of the mitochondria-regulated death pathway. These observations are in line with previous studies demonstrating that T 3 protected ovarian cells from chemotherapy-induced apoptosis through downregulation of BAX and upregulation of BCL-xL 43 . Similarly, TH has been demonstrated to induce mitochondrial biogenesis and activity through positive regulation of autophagy in skeletal muscle cells 44 . Taking these findings together, we propose that, by restoring mitochondrial function, TH therapy allows functional recovery of alveolar epithelial cells, including normalization of mitochondrial bioenergetics and attenuation of mitochondria-regulated apoptosis, which in turn stops the activation of fibroblasts by ROS and damage-associated molecular patterns (DAMPs) and thus allows resolution of fibrosis (Fig. 6f) .
In this study, we did not address several mechanistically relevant questions of interest. For instance, we did not establish the cause for induction of DIO2 in lung fibrosis. Demonstrating a link between mitochondrial dysfunction and upregulation of DIO2 would strengthen the evidence that the mechanism we propose is indeed also relevant in humans. We also did not study in detail the interaction between the antifibrotic effects of TH and the TGF-β signaling pathway, although we demonstrate that aerosolized T 3 therapy is effective in the inducible TGF-β1 model of lung fibrosis. A recent study demonstrated antifibrotic TH effects in models of liver and skin fibrosis 45 . The study proposed that T 3 acts as a modulator of the TGFβ signaling machinery 45 . We did not test this mechanism directly, and it could still be relevant in our models. Similarly, our study focused on the beneficial effects of TH on epithelial cells, and we did not directly evaluate the role of TH in other cells. Metabolic aberrations, senescence and impaired autophagy have been reported in fibroblasts and macrophages in IPF 38, [46] [47] [48] [49] [50] , and it is possible that improved mitochondrial function may also be relevant in these cells. However, we believe that the impressive changes in mitochondrial morphology and function and the dependence of the antifibrotic effects of T 3 on intact PGC-1α and PINK1 pathways in vivo, together with the impressive cytoprotective effects in vitro, support the notion that the antifibrotic effects of TH on mitochondrial homeostasis and function in epithelial cells are key mechanisms in our models, but a direct experimental answer is still missing. Follow-up experiments using cell-type-specific knockout of the TRs will be required to determine whether the antifbrotic effects of TH are cell autonomous or not.
We believe that the observations in subjects with IPF, as well as the detailed and convincing mechanistic experiments we performed in vitro and in animal models of disease, do yield a new and important observation: that TH augmentation, by localized T 3 or systemic sobiterome therapy, enhances resolution of fibrosis in mouse models of pulmonary fibrosis, probably through an epithelial cytoprotective effect. Taken together, our results strongly suggest that strategies using lung-targeted TH therapy should be further studied in IPF.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Histology and immunohistochemistry. Tissue sections (4 µm) were stained with Masson's trichrome (collagen/connective tissue), using two slices per animal and two animals per group, as previously described. Immunostaining for DIO2 (ab77481, Abcam) or PGC-1α (ab54481, Abcam) was performed after paraffin removal, rehydration and blocking, following the recommendations of the manufacturer and a protocol previously described by us 55 . Sections were incubated overnight at 4 °C with primary antibody (diluted 1:100 in PBS) and for 1 h at room temperature with secondary antibody (Sigma). Sections were counterstained with hematoxylin. Primary antibody was replaced by non-immune serum for negative controls.
Hydroxyproline assays. Lung hydroxyproline content was analyzed with a hydroxyproline colorimetric assay kit from Biovision following the manufacturer's instructions, as previously described 59 . Data are expressed as micrograms of hydroxyproline per right lung.
Measurement of serum T 3 levels.
Serum from mouse peripheral blood was collected using BD vacutainers, and total serum T 3 levels were measured using a T 3 ELISA kit (ABIN2685558, Antibodies Online), following the manufacturer's instructions.
Isolation of primary alveolar epithelial cells. Primary AECIIs were isolated from mice treated with 0.9% saline, bleomycin (1.5 U/kg) or bleomycin + aerosolized T 3 (40 µg/kg), using a protocol modified from a previously published method 60 . AECIIs were identified as CD45 − CD32 − CD16 − CD11b − SSc hi cells. Using this protocol, purity of greater than 80% and viability of 90% were obtained. Isolated cells were used for functional assays.
Cell culture experiments, immunofluorescence staining and assays of apoptosis. Human SAECs were purchased from Lonza (lot 000470903). Primary mouse AECIIs were isolated from the lungs of unchallenged mice. A mouse lung epithelial cell line (MLE-12) was purchased from ATCC (CRL-2110). Cells were seeded into 96-well plates (40,000 cells/well), exposed to bleomycin (15 mU/ml) or PBS for 4 h, and then treated with T 3 (15 ng/ml) or vehicle control for 8 h. Immunofluorescence staining was performed using Mito-Tracker (a cationic dye that stains active mitochondria; Thermo Fisher Scientific) and antibody to PGC-1α (ab54481, Abcam), according to the manufacturer's instructions. Detection of apoptotic cells was performed by TUNEL assay using the In Situ Cell Death Detection Kit, Fluorescein (Roche, 11684795910). DAPI staining was used to determine the number of nuclei and to assess gross cell morphology. The A549 human lung adenocarcinoma cell line (ATCC, CCL-185), which tested negative for mycoplasma, was cultured in DMEM supplemented with 10% FBS. Cells were preincubated with either 10 µM dronedarone diluted in 0.04% DMSO or vehicle control (0.04% DMSO) for 24 h and then treated with T 3 (15 ng/ml) or vehicle (0.9% normal saline) for 24 h.
Extracellular flux technology. OCR in primary mouse AECIIs, SAECs and MLE-12 cells was measured using a Seahorse XF96 Extracellular Flux Analyzer (Seahorse Bioscience), as previously described 61 . All assays were performed using a seeding density of 60,000 cells/well in 200 µl of DMEM in an XF96 cell culture microplate (Seahorse Bioscience). Cells were switched to unbuffered DMEM supplemented with 2 mM sodium pyruvate and 20 mM carnosine 1 h before the beginning of the assay and maintained at 37 °C. OCR was measured after sequentially adding to each well 25 µl of oligomycin (an ATP synthase inhibitor), FCCP (a protonophore) and rotenone and antimycin A (inhibitors of complexes I and III) to reach working concentrations of 1 µg/ml, 1 µM and 0.5 µM, respectively. OCR is reported in picomoles per minute per 60,000 cells.
Determination of ATP production. The amount of total ATP was determined using an ATP Fluorometric Assay kit (Biovision) as previously described 61 . Briefly, harvested cultured cells were lysed with lysis buffer followed by centrifugation at 10,000g for 2 min at 4 °C. The level of ATP was determined by mixing 20 µl of the supernatant with 100 µl of luciferase reagent, catalyzing light production from ATP and luciferin. Reactions were performed in six-well plates at a seeding density of 1 × 10 6 cells/well. Luminescence was measured by a monochromator microplate reader. Total ATP levels are expressed as nanomoles per milligram protein.
Mitochondrial membrane potential. Changes in relative MMP (∆Ψ m ) were measured using the JC-10 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-benzamidazolocarbocyanine iodide) molecular probe, as previously described 61 .
Transmission electron microscopy. For TEM, mice were perfused with 4% paraformaldehyde (PFA) and lung samples were dissected out in 2% PFA. These were fixed in 2.5% gluteraldehyde/2% PFA in 0.1 M sodium cacodylate buffer (pH 7.4) for 1 h, followed by rinsing in PBS buffer, and samples were then post-fixed in 1% osmium tetroxide. They were stained en bloc in 2% aqueous uranyl acetate and then rinsed and dehydrated in an ethanol series followed by resin infiltration (Embed 812, Electron Microscopy Sciences) and baked overnight at 60 °C. Hardened blocks were cut using a Leica UltraCut UC7. 60-µm sections were collected on formvar/carbon-coated grids and contrast stained using 2% uranyl acetate and lead citrate. Grids were viewed using FEI TencaiBiotwin TEM at 80 kV. Images were acquired using a Morada CCD and iTEM (Olympus) software. At least ten cells from low-and high-magnification images (11,500× and 26,000×, respectively) were used to count the number of mitochondria per AECII (identified by the presence of lamellar bodies).
Mitobiogenesis assays.
Human SAECs, primary AECIIs isolated from mouse lungs and MLE-12 cells were seeded in 96-well microplates containing 100 µl of culture medium. Cells were first exposed to bleomycin (10 mU/ml) diluted in PBS or vehicle control (PBS) for 4 h and then treated with T 3 (15 ng/ml) or vehicle control for 8 h. The levels of two mitochondrial proteins were measured simultaneously in each well using a colorimetric ELISA kit according to the manufacturer's protocol (MitoBiogenesis In-Cell ELISA Kit, Abcam, ab110217) 17 . The two proteins are subunits of different oxidative phosphorylation enzyme complexes: one protein is subunit I of complex IV (COX-IV), encoded by mitochondrial DNA, and the second protein, SDHA, is a 70-kDa subunit of complex II and is encoded by nuclear DNA.
Immunogold staining protocol. Grids containing tissue samples were placed section side down on drops of 1% hydrogen peroxide for 5 min, rinsed and blocked for nonspecific binding using 3% BSA in Tris-buffered saline containing 1% Triton X-100 for 30 min. Grids were incubated with rabbit primary antibodies to TR-α1 and TR-β (PA1-211A and PA1-213A, respectively, Thermo Fisher, Pierce) at a 1:500 dilution overnight, rinsed in TBS and incubated with 10 nM of secondary antibody conjugated to protein A gold (University of Utrecht, Cell Microscopy Core) for 30 min. The grids were rinsed well in PBS, fixed using 1% gluteraldehyde for 5 min, rinsed again and dried. They were counterstained for heavy metal using 2% aqueous uranyl acetate and lead citrate.
Statistical analysis. Data were statistically analyzed using MedCalc version 14. D' Agostino-Pearson tests were used to test normal distribution. Results were analyzed by Mann-Whitney U test for comparisons of two groups when sample data were not normally distributed, by unpaired Student's t test for comparisons of two groups with normal distribution, and by oneway ANOVA with Student-Newman-Keuls post hoc test for pairwise comparisons of three or more groups. Efficacy experiments were designed for ten animals in the control and treated groups, to allow for 82% power to detect a difference of 20% between the two groups at a statistical significance level of 0.05, but the actual size of groups differed because of mortality or the availability of knockout mice. Data are presented as means ± s.e.m., and differences were considered statistically significant at P < 0.05. Statistical analysis of microarray experiments was performed using BRB array tools as previously described by us 62 . Multiple comparisons were addressed using the FDR method.
Data availability. All high-throughput data mentioned in the paper are publicly available from GEO under accession GSE47460 and at http://www.lung-genomics. org/. All other data that support the findings of this study are available from the corresponding author upon reasonable request.
Life Sciences Reporting Summary. Further information on experimental design and reagents is available in the Life Sciences Reporting Summary.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
MedCalc version 14.
For all studies, we encourage code deposition in a community repository (e.g. GitHub). Authors must make computer code available to editors and reviewers upon request. The Nature Methods guidance for providing algorithms and software for publication may be useful for any submission.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
We did not generate any unique materials
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
The antibodies used PPARGC1A -sc-13067 (rabbit anti-human),and ab-54481(rabbit anti-human and mouse), DIO2-sc-98716(rabbit antihuman), BCL-xL-ab32124(rabbit anti-human), PINK1-ab23707(rabbit antihuman and mouse), LC3B-ab51520(rabbit anti-human and mouse), p62/ SQSTM1-ab56416(mouse anti-human and mouse), BAX-ab32503(rabbit anti-human and mouse) and ab-53154(rabbit anti-human), β-actinsc-47778) Goat anti mouse and human) DIO2-ab77481 (goat anti-mouse), and PPARGC1A-ab54481(rabbit anti-human and mouse)obtained from Santa Cruz Biotechnology, CA (sc), or Abcam, Cambridge, MA (ab). We chose these antibodies by the product data sheets, literature and our pilot studies.
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Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
The study contained data from previously obtained human samples. For gene expression analysis we used the publically available (gene expression omnibus (GEO) GSE47460 and http://www.lung-genomics.org/) LGRC gene expression dataset, generated by our study group. 123 subjects with IPF and 96 control subjects were included. Supplementary Table 1 summarizes the clinical characteristics of the subjects. Supplementary Table 1 
